Teva Pharmaceutical Ownership
TEV Stock | EUR 21.20 0.20 0.95% |
Please note, institutional investors have a lot of resources and new technology at their disposal. They can put in a lot of research and financial analysis when reviewing investment options. There are many different types of institutional investors, including banks, hedge funds, insurance companies, and pension plans. One of the main advantages they have over retail investors is the fees paid for trades. As they are buying in large quantities, they can manage their cost more effectively.
Teva |
Teva Stock Ownership Analysis
About 50.0% of the company shares are owned by institutional investors. The company has price-to-book ratio of 1.16. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. Teva Pharmaceutical has Price/Earnings To Growth (PEG) ratio of 0.75. The entity recorded a loss per share of 1.96. The firm last dividend was issued on the 27th of November 2017. Teva Pharmaceutical had 100:1 split on the 1st of July 2004. Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines and a portfolio of specialty medicines worldwide. Teva Pharmaceutical Industries Limited was founded in 1901 and is headquartered in Petach Tikva, Israel. TEVA PHARMACEUT operates under Drug Manufacturers - Specialty Generic classification in Germany and is traded on Frankfurt Stock Exchange. It employs 42535 people. To find out more about Teva Pharmaceutical Industries contact Kare Schultz at 972 3 914 8213 or learn more at https://www.tevapharm.com.Teva Pharmaceutical Outstanding Bonds
Teva Pharmaceutical issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Teva Pharmaceutical uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Teva bonds can be classified according to their maturity, which is the date when Teva Pharmaceutical Industries has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
Dana 575 percent Corp BondUS235822AB96 | View | |
Volcan Compania Minera Corp BondUSP98047AC08 | View | |
Boeing Co 2196 Corp BondUS097023DG73 | View | |
TEVA 5125 09 MAY 29 Corp BondUS88167AAQ40 | View | |
TEVA 475 09 MAY 27 Corp BondUS88167AAP66 | View | |
US88167AAN19 Corp BondUS88167AAN19 | View | |
HSBC Holdings PLC Corp BondUS404280DR76 | View | |
TEVA 8125 15 SEP 31 Corp BondUS88167AAR23 | View |
Currently Active Assets on Macroaxis
Other Information on Investing in Teva Stock
Teva Pharmaceutical financial ratios help investors to determine whether Teva Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Teva with respect to the benefits of owning Teva Pharmaceutical security.